SITC is pleased to announce a new educational offering for the society’s clinical practice guidelines – SITC’s Cancer Immunotherapy Guidelines Mini Modules. Designed for practitioners with a desire to learn but with limited time, the Mini Modules offer important key takeaways from the evidence- and consensus-based recommendations from the SITC clinical practice guidelines. Each Mini Module is a bite-sized video roughly 10 minutes in length focused on a single topic. Featuring members of the Expert Panel who developed the clinical practice guideline, the Mini Modules and are available here for the following disease and topic areas:
SITC Acute Leukemia CPG Mini Modules
- Antibody-Drug Conjugates
- CAR T Cell Therapy for ALL in Adults
- Sequencing Therapies
SITC Breast Cancer CPG Mini Modules
- First-Line Treatment of Metastatic TNBC
- Toxicities and Adverse Events
- Neoadjuvant and adjuvant treatment
SITC Hepatocellular Carcinoma CPG Mini Modules
- Front-Line Management for Advanced HCC
- IO-IO Therapy in Second-Line Treatment
- Immunotherapy for HCC with Child-Pugh B Cirrhosis
SITC Immune Checkpoint Inhibitor-related Adverse Events CPG Mini Modules
- Autoimmune Disease
- Special Patient Populations
- Vaccines and Chronic irAEs
SITC Immune Effector Cell-related Adverse Events CPG Mini Modules
- CRS and HLH
- ICANS
- Product-specific Toxicity
SITC Lymphoma CPG Mini Modules
- Bispecifics
- CAR T
- Integration with Transplant
SITC Multiple Myeloma CPG Mini Modules
- Antibody-Drug Conjugates
- CAR T and Bispecifics
- Monoclonal Antibodies
SITC Renal Cell Carcinoma CPG Mini Modules
- Management of ccRCC with Large Metastatic Burden
- Management of Toxicities
- Regimens for Challenging Patient Populations
SITC Urothelial Cancer CPG Mini Modules
- Immune Irritability and Management of irAEs
- Management of High-Risk NMIBC
- Treatment of Unresectable Bladder Cancer
SITC Head and Neck Squamous Cell Carcinoma CPG Mini Modules
- Treatment Strategies for Recurrent/Metastatic HNSCC
- Management of Pseudoprogression versus Unresponsive Disease
- Immunotherapy Combinations for Oligometastatic Disease
March 16, 2022